TET vs. VCT, ELM, SCPA, ESNT, SYNT, ZTF, IOF, ITX, WCH, and DCTA
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Victrex (VCT), Elementis (ELM), Scapa Group (SCPA), Essentra (ESNT), Synthomer (SYNT), Zotefoams (ZTF), Iofina (IOF), Itaconix (ITX), Wilmcote Holdings plc (WCH.L) (WCH), and Directa Plus (DCTA). These companies are all part of the "specialty chemicals" industry.
Treatt vs.
Victrex (LON:VCT) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Victrex received 347 more outperform votes than Treatt when rated by MarketBeat users. However, 68.97% of users gave Treatt an outperform vote while only 63.61% of users gave Victrex an outperform vote.
Victrex pays an annual dividend of GBX 60 per share and has a dividend yield of 5.7%. Treatt pays an annual dividend of GBX 8 per share and has a dividend yield of 1.8%. Victrex pays out 17,142.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Treatt pays out 4,444.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Victrex has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Treatt has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
97.1% of Victrex shares are held by institutional investors. Comparatively, 50.9% of Treatt shares are held by institutional investors. 1.6% of Victrex shares are held by company insiders. Comparatively, 13.4% of Treatt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Victrex has a net margin of 10.81% compared to Treatt's net margin of 7.88%. Treatt's return on equity of 8.46% beat Victrex's return on equity.
Victrex has higher revenue and earnings than Treatt. Treatt is trading at a lower price-to-earnings ratio than Victrex, indicating that it is currently the more affordable of the two stocks.
Victrex presently has a consensus target price of GBX 1,425, indicating a potential upside of 35.20%. Treatt has a consensus target price of GBX 675, indicating a potential upside of 52.20%. Given Treatt's stronger consensus rating and higher possible upside, analysts plainly believe Treatt is more favorable than Victrex.
In the previous week, Victrex had 1 more articles in the media than Treatt. MarketBeat recorded 4 mentions for Victrex and 3 mentions for Treatt. Victrex's average media sentiment score of 0.45 beat Treatt's score of 0.25 indicating that Victrex is being referred to more favorably in the media.
Summary
Victrex beats Treatt on 11 of the 20 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:TET) was last updated on 1/21/2025 by MarketBeat.com Staff
